ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates

分组1 - ImmunoPrecise Antibodies Ltd. reported a quarterly loss of $0.06 per share, which aligns with the Zacks Consensus Estimate, showing an improvement from a loss of $0.08 per share a year ago [1] - The company's revenues for the quarter ended January 2025 were $4.33 million, missing the Zacks Consensus Estimate by 12.19% and down from $4.6 million year-over-year [2] - Over the last four quarters, ImmunoPrecise Antibodies has consistently failed to surpass consensus EPS and revenue estimates [2][6] 分组2 - The stock has increased approximately 7% since the beginning of the year, contrasting with a -3.2% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $5.02 million, and for the current fiscal year, it is -$0.27 on revenues of $18.02 million [7] - The Medical Info Systems industry, to which ImmunoPrecise belongs, is currently ranked in the top 17% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]